The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1
Abstract
BACKGROUND: New trends in immunosuppression in clinical transplantation include the use of antibody induction agents in protocols that emphasize reduction or avoidance of steroids and calcineurin inhibitors. METHODS: In a randomized trial using three different antibody induction agents in 90 first renal transplant recipients from cadaver donors, group A received Thymoglobulin, group B received Alemtuzumab, and group C received Daclizumab. Maintenance immunosuppression included tacrolimus and mycophenolate in all three arms, and methylprednisolone in groups A and C only (standard clinical institutional practice). The targeted trough level of tacrolimus was between 8 and 10 ng/mL for groups A and C, respectively, with a targeted mycophenolate dose of 1 g twice daily. However, in group B, the target tacrolimus trough level was 4 to 7 ng/mL to reduce long-term nephrotoxicity, with 500 mg twice-daily doses of mycophenolate, without steroid maintenance. RESULTS: In this 15-month median postoperative interval report, there were no notable differences in demographics and patient and graft survivals. Acute rejection rates at 1 year were equivalent, that is, 5 of 30 in all three groups (16.6%). In group B, there was slightly lower renal function at 1 month, but no difference at 1 year. There was also significantly more leukopenia, but a greater percentage of T-regulatory cells and number of Fox-P3 mRNA copies by flow cytometry and semiquantitative polymerase chain reaction analysis, respectively, in group B. CONCLUSIONS: This preliminary analysis indicates that 80% of the patients in group B remained steroid-free 1 year postoperatively, with lower tacrolimus trough levels and no difference in other adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Cited by
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Delayed Graft Function in the Kidney Transplant
Siedlecki, A., Irish, W., & Brennan, D. C. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03754.x · Cited by 817
Alemtuzumab Induction in Renal Transplantation
Hanaway, M. J., Woodle, E. S., Mulgaonkar, S., Peddi, V. R., Kaufman, D. B., First, M. R., Croy, R., & Holman, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009546 · Cited by 383
Flechner, S. M., Kobashigawa, J., & Klintmalm, G. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00739.x · Cited by 310
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Metadata
- Authors
- Ciancio, G., Burke, G. W., Gaynor, J. J., Carreno, M. R., Cirocco, R. E., Mathew, J. M., Mattiazzi, A., Cordovilla, T., Roth, D., Kupin, W., Rosen, A., Esquenazi, V., Tzakis, A. G., & Miller, J.
- Venue
- Transplantation
- Published
- 2005-08
- Volume
- 80
- Issue
- 4
- Pages
- 457-465
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2000138932
- Cited by
- 220
- References
- 1
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1. https://app.cochat.ai/papers/10.1097/01.tp.0000165847.05787.08
- The paper
- Ciancio, G., Burke, G. W., Gaynor, J. J., Carreno, M. R., Cirocco, R. E., Mathew, J. M., Mattiazzi, A., Cordovilla, T., Roth, D., Kupin, W., Rosen, A., Esquenazi, V., Tzakis, A. G., & Miller, J. (2005). A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1. Transplantation. https://doi.org/10.1097/01.tp.0000165847.05787.08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.